{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:34:54Z","timestamp":1792121694218,"version":"4.4.0"},"reference-count":16,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Increased absolute lymphocyte count (ALC) may predict risk of treatment-related mortality and atypical neurologic events among patients receiving chimeric antigen receptor (CAR) T-cell therapies for relapsed\/refractory multiple myeloma. In this study, we analyzed the clinical outcomes of patients receiving ciltacabtagene autoleucel (cilta-cel) at the Colorado Blood Cancer Institute, from September 2023 to January 2025. Baseline data were collected pre\/post-CAR T-cell therapy. Patients were stratified into preintervention (treated September 2023 to July 2024) and intervention (treated August 2024 to January 2025; those with ALC &amp;gt;5 \u00d7 103\/\u03bcL received 3 days of dexamethasone prophylaxis on first identification of elevated ALC). In the preintervention group, 9 of 30 patients had peak ALC &amp;gt;5 \u00d7 103\/\u03bcL; 5 of 9 (55.6%) experienced atypical neurologic events and all 5 died (cilta-cel therapy-related complications). In the intervention group, 7 of 23 patients had peak ALC &amp;gt;5 \u00d7 103\/\u03bcL and received dexamethasone; 1 of 7 had an atypical neurologic event; and 1 death occured (infectious complication, 9 months posttreatment). Dexamethasone prophylaxis in patients with ALC of &amp;gt;5 \u00d7 103\/\u03bcL resulted in rapid ALC reduction. Overall survival (OS) was significantly lower in preintervention patients with ALC of &amp;gt;5 \u00d7 103\/\u03bcL vs intervention patients with ALC of &amp;gt;5 \u00d7 103\/\u03bcL and patients with ALC of \u22645 \u00d7 103\/\u03bcL (P = .0013). ALC &amp;gt;5 \u00d7 103\/\u03bcL (vs ALC \u2264 5 \u00d7 103\/\u03bcL) was significantly associated with atypical neurologic events (odds ratio, 6.8; P = .0157) and lower OS (hazard ratio, 6.2; P = .0106). In conclusion, ALC &amp;gt;5 \u00d7 103\/\u03bcL after cilta-cel treatment predicted severe early neurologic events and high mortality risk. Dexamethasone prophylaxis demonstrated promise for risk mitigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018639","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T20:54:42Z","timestamp":1774644882000},"page":"3629-3639","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Dexamethasone prophylaxis for excessive lymphocyte expansion after cilta-cel in multiple myeloma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3248-7530","authenticated-orcid":false,"given":"Peter A.","family":"Forsberg","sequence":"first","affiliation":[{"name":"1Colorado Blood Cancer Institute\/Sarah Cannon Cancer Network, HCA-HealthONE P\/SL, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline A.","family":"Turner","sequence":"additional","affiliation":[{"name":"1Colorado Blood Cancer Institute\/Sarah Cannon Cancer Network, HCA-HealthONE P\/SL, Denver, CO"},{"name":"2Department of Medicine, University of Colorado School of Medicine, Aurora, CO"},{"name":"3Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN"},{"name":"4Department of Internal Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita","family":"Meyer","sequence":"additional","affiliation":[{"name":"1Colorado Blood Cancer Institute\/Sarah Cannon Cancer Network, HCA-HealthONE P\/SL, Denver, CO"},{"name":"5Dartmouth Hitchcock Medical Center, Lebanon, NH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Abbott","sequence":"additional","affiliation":[{"name":"1Colorado Blood Cancer Institute\/Sarah Cannon Cancer Network, HCA-HealthONE P\/SL, Denver, CO"},{"name":"2Department of Medicine, University of Colorado School of Medicine, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Nicholson","sequence":"additional","affiliation":[{"name":"1Colorado Blood Cancer Institute\/Sarah Cannon Cancer Network, HCA-HealthONE P\/SL, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Schade","sequence":"additional","affiliation":[{"name":"1Colorado Blood Cancer Institute\/Sarah Cannon Cancer Network, HCA-HealthONE P\/SL, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Matous","sequence":"additional","affiliation":[{"name":"1Colorado Blood Cancer Institute\/Sarah Cannon Cancer Network, HCA-HealthONE P\/SL, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Gregory","sequence":"additional","affiliation":[{"name":"1Colorado Blood Cancer Institute\/Sarah Cannon Cancer Network, HCA-HealthONE P\/SL, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"issue":"6","key":"2026052610370664400_bib1","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026052610370664400_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"2026052610370664400_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026052610370664400_bib4","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1182\/blood-2024-201783","article-title":"Delayed neurotoxicity after CAR-T in multiple myeloma: results from a global IMWG registry","volume":"144","author":"Kumar","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026052610370664400_bib5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"10297","key":"2026052610370664400_bib6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"25","key":"2026052610370664400_bib7","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"issue":"23","key":"2026052610370664400_bib8","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2024028172","article-title":"Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment","volume":"145","author":"Blumenberg","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026052610370664400_bib9","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood-2024-194390","article-title":"Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in relapsed or refractory multiple myeloma [abstract]","volume":"144","author":"Hansen","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026052610370664400_bib10","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1038\/s41467-025-60980-2","article-title":"Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma","volume":"16","author":"Atanackovic","year":"2025","journal-title":"Nat Commun"},{"issue":"2 suppl","key":"2026052610370664400_bib11","first-page":"S215","article-title":"Prophylactic dexamethasone rescues unrestrained lymphocyte expansion in anti-BCMA chimeric antigen receptor T cell therapy in multiple myeloma [abstract]","volume":"31","author":"Turner","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"suppl 1","key":"2026052610370664400_bib12","doi-asserted-by":"crossref","first-page":"S965","DOI":"10.1016\/S2152-2650(25)02685-0","article-title":"Absolute lymphocyte count as a key biomarker for monitoring safety after ciltacabtagene autoleucel [abstract]","volume":"25","author":"Lin","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2 suppl","key":"2026052610370664400_bib13","first-page":"S202","article-title":"Risk factors for delayed neurotoxicity in patients with relapsed myeloma who received ciltacabtagene autoleucel (cilta-cel)","volume":"31","author":"Lim","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"14","key":"2026052610370664400_bib14","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1182\/bloodadvances.2024015721","article-title":"Intrathecal chemotherapy for ciltacabtagene autoleucel\u2013associated movement and neurocognitive toxicity","volume":"9","author":"Kelly","year":"2025","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026052610370664400_bib15","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/blood-2025-4586","article-title":"Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in relapsed\/refractory multiple myeloma (RRMM)","volume":"146","author":"Rana","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026052610370664400_bib16","doi-asserted-by":"crossref","first-page":"S566","DOI":"10.1016\/S2152-2650(24)01698-7","article-title":"Effectiveness of bridging therapy corresponds to improved outcomes after receiving CAR-T therapy: phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma [abstract]","volume":"24","author":"Lin","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3629\/2519779\/blooda_adv-2025-018639-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3629\/2519779\/blooda_adv-2025-018639-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:37:13Z","timestamp":1779806233000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/10\/3629\/567462\/Dexamethasone-prophylaxis-for-excessive-lymphocyte"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018639","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,26]]},"published":{"date-parts":[[2026,5,15]]}}}